Lifeboat Foundation

Neuroscience

Psilocybin — the hallucinogenic ingredient in mushrooms — may help in depression, a study suggests.

https://www.youtube.com/watch?v=HOTS0HS7aq4

As part of the LEAF Longevity Bookclub and to celebrate the launch of Dr. David Sinclair’s new book, Lifespan: Why We Age and Why We Don’t Have To, we hosted a special webinar on the 18th of September. The new book takes us on a journey through the biology of why we age and spotlights the exciting research being done in the lab today which could potentially change the way we treat the diseases of aging.

Continue reading “Dr. David Sinclair Webinar – Lifespan: Why We Age – and Why We Don’t Have To” »

Vision Weekend is the annual member gathering of Foresight Institute, a non-profit for advancing beneficial technologies for the long-term flourishing of life.

More info on speakers and program: https://foresight.org/vision-weekend-2019/.
Join Foresight Institute’s community: www.bit.ly/foresightnews

John and Charlotte Henderson, who met at the University of Texas Austin in 1934 and wed five years later, have been recognized by Guinness World Records for the longevity of their love.

Drugs can cause permanent harm to the brain. We’re only beginning to find ways to heal the hurt.

With companies offering free shipping to gain a competitive edge, radical new technologies are being tested to cut the cost of the supply chain’s expensive “last mile”.

Tao has made huge progress on the Collatz conjecture, a simple-seeming puzzle that has bedeviled hapless mathematicians for decades.

Scientists from the Salk Institute for Biological Studies are homing in on exactly how two new experimental Alzheimer’s drugs could be generating the anti-aging effects seen in early animal studies. The discovery of a unique metabolic pathway, associated with both general aging and the onset of dementia, offers researchers novel directions for future anti-aging studies.

Salk researchers have been developing two experimental drugs for several years with a view on improving cognition and slowing the neurodegenerative decline associated with Alzheimer’s disease. Called CMS121 and J147, the drugs were effective in slowing the progression of Alzheimer’s in initial animal tests. However, the compounds also seemed to demonstrate signs of slowing down general markers of brain aging.

As the two drugs move toward human trials, the researchers have been working to uncover exactly what molecular mechanisms are at play to explain how they work. One potential mechanism was uncovered in early 2018 but that was only part of the story. Now, the Salk team has uncovered an exciting new molecular pathway, influenced by the two drugs, that could explain how the compounds slow down brain aging.